Investors & Media

Investor Relations



NASDAQ: TGTX
Price
5.27
Change
+ 0.14
Day High
5.40
Day Low
4.89
Volume
112,300
4:00 PM ET on Apr 17, 2014
Stock price graph
     

TG Therapeutics, Inc.  is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐cell lymphocytes. TG Therapeutics is headquartered in New York City.

View all »   RSSRecent Releases

Apr 7, 2014
TG Therapeutics, Inc. Announces Preclinical Poster Presentations for TGR-1202 at AACR 2014

Mar 11, 2014
TG Therapeutics, Inc. Announces $18.1 Million Underwritten Sale of Common Stock to a Single Institutional Investor